1. Scrip

Global First Approval For Takeda's Dengue Vaccine, In Indonesia

Set To Open Door To Wider Vaccine Use?

 
• By Lisa Takagi

Takeda’s dengue vaccine Qdenga has received its global first approval in Indonesia, as Qdenga, also marking the first time for the firm to market a vaccine outside Japan and potentially paving the way to wider global use of vaccines for the mosquito-borne disease following setbacks for earlier contenders. 

Takeda's Qdenga, also known as TAK-003, received its global first approval
Takeda's Qdenga awaiting regulatory approval in Europe and the US • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd.’s live, attenuated tetravalent dengue vaccine Qdenga (TAK-003) has received its global first approval, in Indonesia, for the prevention of disease caused by any serotype in individuals aged six to 45 years of age.

The nod, granted by the National Agency for Drug and Food Control (Badan Pengawas Obat dan Makanan: BPOM), makes the product the only dengue vaccine approved locally without a need for pre-vaccination testing and regardless of previous dengue exposure

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.